MarketVIEW: Hepatitis E Virus (HEV) vaccines (CAT: VAMV040)

Product Name : MarketVIEW: Hepatitis E Virus (HEV) vaccines
Description : Global vaccine commercial opportunity assessment
Contents : Executive presentation + 1 forecast model
Therapeutic Area : Hepatitis vaccines
Publication date : February 2013
Catalogue No : VAMV040

Background

Hepatitis E Virus (HEV) is most common in developing countries with inadequate water supply and environmental sanitation. The virus is enterically transmitted via the faecal-oral route and has been responsible for many large outbreaks. Every year it is estimated to infect about 20 million people, cause 3.3 million incident cases and claim 70,000 lives. Although HEV usually causes a self-limited acute illness in humans the virus disproportionately affects pregnant women with a probability of death estimated at ~20%.

In December 2011 the first HEV vaccine “Hecolin” was approved by China’s State Food and Drug Administration (SFDA). The product is marketed by the subsidiary company Innovax formed by Yangshengtang Group and Xiamen University in Fujian province. Hecolin is pending the WHO prequalification program so could be used outside of China in the future.

This MarketVIEW product contains an executive presentation with an MS Excel-based model which forecasts the potential commercial value of Hepatitis E Virus (HEV) vaccines across the private sector of highly endemic and endemic markets until 2030. The model contains value ($ m) and volume (mio doses) predictions along with timeframe, pricing and penetration estimates for all adult risk groups (>16 yrs) including immunocompromised, women of child bearing-age and military personnel.
Methodology

VacZine Analytics has closely monitored all significant source material pertaining Hepatitis E Virus (HEV) epidemiology, disease indications and target groups. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by VacZine Analytics in the field of viral pathogens has also been utilised.

PRODUCT CONTENTS:
Published February 2013 (CAT No: VAMV040)

****This product is composed of one forecast model and a summary presentation

Contents
Executive Summary
Author’s Note
Key model outputs
Hepatitis E vaccine: global revenues ($ 000s) - per scenario
Hepatitis E vaccine: global volumes (Doses 000s) - per scenario
Hepatitis E vaccine: global revenues ($ 000s) - region
Hepatitis E vaccine: global volumes (Doses 000s)* - per region
Hepatitis E virus - Disease background and epidemiology
Endemicity of Hepatitis E Virus (HEV)
Endemicity of Hepatitis E Virus (HEV): list of countries
Selected Large Reported Outbreaks of Hepatitis E Virus (HEV)
Hepatitis E infection: morbidity & mortality
Hepatitis E virus: genetic diversity
Geographical distribution of HEV disease pattern
Characteristics of HEV infections according to genotype
Hepatitis E virus: transmission
Routes of Hepatitis E virus infection
Time course of Hepatitis E virus infection
Hepatitis E virus: risk groups
Hepatitis E infection: diagnosis/clinical description
Clinical findings in Hepatitis E outbreaks
Hepatitis E: age distribution of cases (Hong Kong 2001-2010)
Comparison of major characteristics between HAV and HEV
Hepatitis E virus: focus on pregnant women
Hepatitis E virus: focus on neonates
Hepatitis E virus: chronic infection
Hepatitis E virus: Solid-organ transplant recipients
Hepatitis E infection: treatment/management
Hepatitis E virus: summary of vaccine development
Hepatitis E vaccines: biological rationale
Hepatitis E vaccines: current status
Hecolin (Innovax) - HEV239
HEV239: late stage clinical data
Hepatitis E vaccine: GlaxoSmithKline/WRAIR
GlaxoSmithKline/WRAIR: Phase II clinical data
Hepatitis E vaccines: other programs
Hepatitis E vaccine: modelling commercial potential
Hepatitis E vaccines: modelling methodology
Continued..........

Countries modelled (private sector)
HEV vaccine: modelling scenarios (private sector)
Commercial model assumptions: highly endemic countries
Commercial model assumptions: endemic countries
Hepatitis E vaccines: public sector use
Hepatitis E vaccines: model caveats/limitations
Bibliography
About VacZine Analytics
Disclaimer

PAGES: ~60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Title sheet
CHARTS – TOTAL per scenario
CHARTS – TOTAL per region
Value/ Volume per scenario
Val sum (highly endemic)
Pricing highly endemic
Val sum (endemic)
Pricing endemic
Vol sum (highly endemic)
Vol sum (endemic)
Highly endemic markets ➔
LATAM (a) (>16 yrs at risk)
AFRICA (a) (>16 yrs at risk)
MENA (a) (>16 yrs at risk)
ASIA (a) (>16 yrs at risk)
INDIA (>16 yrs at risk)
CHINA (>16 yrs at risk)
Endemic markets ➔
LATAM (a) (>16 yrs at risk)
M5EU (>16 yrs at risk)
OTHER EU (a) (>16 yrs at risk)
AFRICA (a) (>16 yrs at risk)
MENA (a) (>16 yrs at risk)
ASIA (a) (>16 yrs at risk)
Population sources ➔
>16 yrs (highly endemic)
>16 yrs (endemic)
20-44 yrs Females (highly endemic)
20-44 yrs Females (endemic)
Military (highly endemic)
Military (endemic)
>16 yrs ALL COUNTRIES
20-44 yrs ALL COUNTRIES
% PRIVATE SECTOR
AT RISK POPULATIONS
WORLD MILITARIES

Worksheets = 40 interconnected
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD $8495.00/ GBP £5480.00 (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 20% will be added to final invoice total
# - indicative prevailing rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.
BIBLIOGRAPHY


37. Safary A. Perspectives of vaccination against hepatitis E. Intervirology. 2001;44:162 http://dx.doi.org/10.1159/000050043


TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.

2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.

3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.

4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.

5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.

6. If not purchased on line invoices are payable within thirty days of the invoice date.

7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.

8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.

9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

*VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009*